美国食品药品管理局(FDA)于2011年8月4日发布药物安全公告:尚未确定重组人生长激素可增加死亡风险。此次信息是针对FDA于2010年12月22日发布的相关安全信息的更新。重组人生长激素是一种使用DNA重组技术生产的与人体自身分泌的生长激素接近的蛋白质。在美国,重组人生长激素被批准用于治疗小儿由于生长激素缺乏而致的身材矮小(包括先天性生长激素缺乏)、特纳综合征、努南综合征、普瑞德威利症候群等。 The U.S. Food and Drug Administration (FDA) issued a drug safety bulletin on August 4, 2011: It has not been established that recombinant human growth hormone can increase the risk of death. This information is for the FDA on December 22, 2010 release of relevant safety updates. Recombinant human growth hormone is a protein that is produced using DNA recombination technology and is similar to the growth hormone secreted by the body itself. In the United States, recombinant human growth hormone is approved for the treatment of short stature (including congenital growth hormone deficiency) in children due to a lack of growth hormone, Turner syndrome, Noonan syndrome, Purdue Wallerian syndrome and others.